Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Antibody Drug Conjugate Development Services

As a hotspot of anti-cancer drug development, antibody-drug conjugates (ADCs) are usually formed by covalently linking monoclonal antibodies (mAbs) to cytotoxic drugs via chemical linkers, which combine the advantages of high specific targeting ability and potent killing effects. Alfa Cytology provides antibody drug conjugate development services to help customers realize precise and efficient cancer cell elimination.

Introduction to Antibody Drug Conjugate

Chemotherapy based on cytotoxic drugs has been the mainstay of therapy for various cancers for decades. However, most of these chemotherapeutic agents have a low therapeutic index, and severe side effects are usually due to drug exposure to non-specific target tissues. On the other hand, the emergence of mAb has changed the paradigm of cancer therapy by precisely targeting tumor surface antigens. However, therapy with mAb alone is often ineffective compared to chemotherapy.

As a result, a new concept called antibody drug conjugates has emerged to bridge the gap between mAb and cytotoxic drugs to improve the therapeutic window. With expanding targets and indications, ADCs are ushering in a new era of targeted cancer therapy and are expected to replace conventional chemotherapy in the future.

Our Services

Alfa Cytology understands the dynamics and complexities of the current ADC technology landscape and is well-versed in various ADC technologies. We utilize our expertise to identify and map the appropriate design space for the development of your ADCs for cancer therapeutics.

scFv

Antibody Development and Screening Services

Tumor-targeting antibodies are important for specific binding between target antigens and ADCs. In addition to high binding affinity to the target antigen, the ideal antibody portion should also promote effective internalization, exhibit low immunogenicity, and maintain a long plasma half-life. Alfa Cytology considers several factors such as affinity, specificity, tumor penetration, and half-life to provide customers with the optimal tumor-targeting antibodies.

Nanobodies

Cytotoxic Payload Screening and Optimization Services

Cytotoxic payloads are warheads that exert cytotoxicity after ADC internalization into cancer cells. Payload compounds need to be highly potent, stable under physiological conditions, and have functional groups that can be conjugated to antibodies. We offer several different classes of payloads, including traditional cytotoxic payloads, including potent microtubule protein inhibitors and DNA damaging agents, as well as payloads with novel mechanisms, such as small molecule immunomodulators.

Polyvalent Antibody Fragments

Linker Design and Optimization Services

The linker in the ADC bridges the antibody to the cytotoxic drug. It is one of the key factors associated with ADC stability and payload release profile, which is therefore important for the ultimate therapeutic index of the ADC. We provide design and synthesis services for ADC linkers and linker-drug conjugates. Depending on the drug release mechanism, we design and synthesize different ADC linkers, including cleavable and non-cleavable linkers, self-incinerating tracer-free linkers, and peptide linkers.

Polyvalent Antibody Fragments

Conjugation Approaches Services

In addition to the choice of antibody, linker, and payload, the method by which the small molecule portion, i.e., the junction plus the payload, is conjugated to the antibody is also important for the successful construction of ADCs. Our team provides efficient ADC conjugation services to accelerate the production of ADC constructs with superior properties. Our techniques include, but are not limited to, amine (Lys) conjugation, thiol (Cys) conjugation, site-specific conjugation, enzyme conjugation, sugar conjugation, and click chemistry.

Workflow of Antibody Drug Conjugate Development

01. Target Selection

Selection of cancer-associated antigens suitable as ADC targets.

02. Component Selection

Selection of the antibody, cytotoxin and linker for following ADC synthesis.

03. Synthesis of ADC

Chemical reaction of the selected antibody with the linking drug to form ADC.

04. ADC Characterization

Evaluate ADCs for purity, stability, solubility and dissolution.

05. Preclinical Evaluation

The ADME/PK.antitumor activity, efficacy, and other properties are assessed.

Candidate ADC Drug

Our Advantages

Largest Toolbox

Largest Toolbox

Strong Expertise

Strong Expertise

One-stop Solution

One-stop Solution

Short Turnaround

Short Turnaround

Altering any of the three crucial components can significantly impact the overall efficacy of the ADC, highlighting the critical importance of maintaining the integrity and compatibility of each element. Alfa Cytology has many years of experience in ADC development, providing customers with the identification and validation of new antigens/antibodies, the development of new payloads with optimal toxicity, and the design of new linkers that balance the stability and payload release. Please contact us for more information.

Reference

Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal transduction and targeted therapy, 7(1), 93. https://doi.org/10.1038/s41392-022-00947-7

For research use only.